Patient Adherence Program Design

Not Found

Sorry, but no results were found. Please use our navigation or search to find what you are looking for.

How will the HHS proposed rule changes to Medicare Part D and Medicaid drug rebate safe harbors impact pharmaceutical product net costs for PBMs?

Higher net costs after the implementation of the proposed rule: 50%

Lower net costs after the implementation of the proposed rule: 12.5%

No impact, net costs will be at the same levels as today: 37.5%

What is the likelihood brand pharmaceutical manufacturers will slow drug price increases in 2019 based on the Trump administration’s proposals?

Highly Likely: 0%

Likely: 12.5%

Unlikely: 75%

Highly Unlikely: 12.5%

Are there more challenges with the new lower priced Repatha NDC compared with the higher priced NDC?

Yes: 57.1%

No: 42.9%

Do you think brand manufacturer’s strategy to introduce a lower priced brand NDC of an existing product is going to expand in 2019?

Yes: 85.7%

No: 14.3%